Vesiflo's inFlow™ Voiding Prosthesis Receives National Pricing
Vesiflo, Inc. has achieved a significant milestone in patient care with the national pricing for its inFlow™ Voiding Prosthesis, a groundbreaking device designed to replace traditional urinary catheters. This advancement follows the essential decision by the Centers for Medicare & Medicaid Services (CMS) to set national pricing for the CPT codes associated with the device, ensuring consistent treatment options for women living with permanent urinary retention (PUR).
Transforming Patient Care for Urinary Retention
The inFlow Voiding Prosthesis presents an innovative solution for women suffering from conditions that necessitate chronic urinary catheter use. With the CMS's decision, effective January 1, 2026, patients will gain wider access to this life-enhancing technology. Previously, the medical community has recognized the importance of this device, noting strong support from physicians highlighting its benefits.
Revolutionizing Urological Management
Kevin Connolly, the CEO of Vesiflo, emphasized the significant role that CMS leadership plays in facilitating access to enhanced healthcare solutions. He stated, "The inFlow voiding prosthesis is the only viable alternative available for women with permanent urinary retention due to neuromuscular issues, including conditions like multiple sclerosis and spinal cord injuries. We are dedicated to expanding our efforts to serve patients in urgent need of this technology."
Expert Opinions on the inFlow Technology
Dr. Richard Schmidt, a notable figure in urological medicine and co-inventor of Medtronic’s InterStim, commended the clinical implications of the inFlow device. He mentioned, "This device is a breakthrough, as it effectively replicates the natural function of the bladder, providing a much-needed alternative for women who require chronic catheterization." His endorsement highlights the transformative nature of inFlow for those seeking improved quality of life.
How the inFlow Technology Works
Unlike conventional catheters that rely on passive urine drainage, the inFlow prosthesis employs advanced technology to actively empty the bladder. This process mimics natural urination, allowing users to engage with their daily life more comfortably and enabling normal toilet use. By restoring this essential act, the inFlow not only enhances health outcomes but also reinstates dignity and independence for its users.
Positive Clinical Outcomes
Clinical research has demonstrated that individuals utilizing the inFlow experience a reduced incidence of urinary tract infections and notable improvements in their overall health compared to those relying on traditional clean intermittent catheterization (CIC). This evidence underlines the importance of developing innovative medical devices that prioritize patient quality of life.
About Vesiflo, Inc.
Vesiflo is a pioneering medical device company based in Redmond, Washington, focusing on creating innovative alternatives to outdated urinary catheter methods. With the introduction of the inFlow Voiding Prosthesis, the company aims to redefine bladder management solutions, boosting the quality of life for those facing chronic urological challenges.
Contact Information
For further inquiries, please reach out to Kevin Connolly, CEO, at 425-242-6373.
Frequently Asked Questions
What is the inFlow Voiding Prosthesis?
The inFlow Voiding Prosthesis is a revolutionary device designed to allow women suffering from permanent urinary retention to manage their condition without traditional catheters.
Who will benefit from the inFlow device?
Women facing permanent urinary retention due to neurological conditions such as multiple sclerosis and spinal cord injuries will significantly benefit from the inFlow device.
How does the inFlow technology differ from standard catheters?
In contrast to standard catheters, the inFlow actively empties the bladder using advanced technology that duplicates the body's natural urination process.
When will the CMS national pricing for inFlow take effect?
The national pricing for the inFlow Voiding Prosthesis established by CMS will come into effect on January 1, 2026.
What positive impacts does inFlow have on patient health?
Clinical studies have shown that inFlow users experience fewer urinary tract infections and enhanced quality of life compared to traditional catheter users.
